Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP874335.RAr-rUJhnKc5kMDbPlsA7SMu07aGwWqmE55CqP_-mPpOw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP874335.RAr-rUJhnKc5kMDbPlsA7SMu07aGwWqmE55CqP_-mPpOw130_assertion type Assertion NP874335.RAr-rUJhnKc5kMDbPlsA7SMu07aGwWqmE55CqP_-mPpOw130_head.
- NP874335.RAr-rUJhnKc5kMDbPlsA7SMu07aGwWqmE55CqP_-mPpOw130_assertion description "[We hypothesized that bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), will potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of the head and neck (SCCHN).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP874335.RAr-rUJhnKc5kMDbPlsA7SMu07aGwWqmE55CqP_-mPpOw130_provenance.
- NP874335.RAr-rUJhnKc5kMDbPlsA7SMu07aGwWqmE55CqP_-mPpOw130_assertion evidence source_evidence_literature NP874335.RAr-rUJhnKc5kMDbPlsA7SMu07aGwWqmE55CqP_-mPpOw130_provenance.
- NP874335.RAr-rUJhnKc5kMDbPlsA7SMu07aGwWqmE55CqP_-mPpOw130_assertion SIO_000772 21343546 NP874335.RAr-rUJhnKc5kMDbPlsA7SMu07aGwWqmE55CqP_-mPpOw130_provenance.
- NP874335.RAr-rUJhnKc5kMDbPlsA7SMu07aGwWqmE55CqP_-mPpOw130_assertion wasDerivedFrom befree-2016 NP874335.RAr-rUJhnKc5kMDbPlsA7SMu07aGwWqmE55CqP_-mPpOw130_provenance.
- NP874335.RAr-rUJhnKc5kMDbPlsA7SMu07aGwWqmE55CqP_-mPpOw130_assertion wasGeneratedBy ECO_0000203 NP874335.RAr-rUJhnKc5kMDbPlsA7SMu07aGwWqmE55CqP_-mPpOw130_provenance.